Abstract:Young women with breast cancer are at higher risk of locoregional recurrence in comparison with elder women. The study aimed to determine the factors related to locoregional recurrence and the impact of post-mastectomy radiotherapy in women ≤35 years old. Between February 1989 and December 2004, 459 patients ≤35 years old with operable breast cancer who treated mastectomy were retrospectively analyzed. The type of surgery included: radical mastectomy (47.4%), extended radical mastectomy (11.5%) and modified radical mastectomy (MRM; 39.6%). The percentage for T1, T2, and T3 tumor was 22.0%, 52.3%, and 10.0%, respectively. Lymph node without metastasis accounted for 25.7% of all and N1, N2, and N3 lymph node accounted for 25.5%, 20.7%, and 14.6%. Four hundred twenty-three patients received chemotherapy and 160 patients received endocrine therapy. PMRT was administered in 220 patients (47.9%). Radiation field included supraclavicular lymph node and internal mammary nodes only in 187 and 170 patients while chest wall was treated in 25 patients. Median age of this cohort was 32 years old and median follow-up was 50.1 months. The median disease-free interval to first isolated locoregional recurrence was 17.8 ± 2.7 months. The 5-year and 10-year isolated locoregional control rate (ILRCR) was 74.9% and 70.0%, respectively. The most common site of recurrence was CW (106/131) followed by SN (18/131). The 5-year CW control rate decreased with more advanced T and N Stage (p<0.05). Compared to the patients with no ILR, patients with ILR had a shorter 5-year metastasis-free survival (MFS) (66.6% vs. 53.8%; p = 0.003). In univariate analysis, surgical modality, tumor size, lymph node status, chemotherapy and ILR were significant predictors for overall survival (OS). In multivariate analysis, only higher T-Stage (p = 0.041; HR = 1.69; 95% CI = 1.02 – 2.16) was the independent predictor for isolated chest-wall recurrence (ICWR) while higher N-Stage (p = 0.005; HR = 1.58; 95% CI = 1.15 – 2.78) was the additional predictor for ILR besides higher T-Stage (p = 0.047; HR = 1.58; 95% CI = 1.02 – 2.42). Higher T-Stage (p = 0.014; HR = 1.52; 95% CI = 1.09 – 2.12), higher N-Stage (p < 0.001; HR = 2.25; 95% CI = 1.67 – 3.03), the use of endocrine therapy (p = 0.014; HR = 0.59; 95% CI = 0.39 – 0.90) and ICWR (p = 0.006; HR = 1.87; 95% CI = 1.20 – 2.91) are independent predictors for MFS. As to OS, all factors above were independent prognostic factors for OS except for the endocrine therapy administration (p > 0.05). Young women with operable breast cancer receiving mastectomy have a high risk of ILR and shorter disease-free interval. It is critical to re-evaluate the impact of PMRT in young patients. Chest-wall remains the region with higher risk of recurrence and should not be neglected as PMRT target.

P268 Frequency and Anatomical Characteristics of Involved Regional Lymph Nodes in Recurrent and Advanced Breast Cancer

Locoregional Recurrence Analysis in Young Women (≤35 Years) Receiving Mastectomy with Operable Breast Cancer

67P Analysis of Local-Regional Recurrence in Young Women (≤ 35Y) Receiving Mastectomy for Operable Breast Cancer

The Locoregional Recurrence Risk and Failure Pattern for Breast Cancer Patients with 1 to 3 Positive Nodes and Treated with Mastectomy and Contemporary Systemic Therapy

Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.

Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?

Locoregional Recurrence-Associated Factors and Risk-Adapted Postmastectomy Radiotherapy for Breast Cancer Staged in Ct1-2N0-1 after Neoadjuvant Chemotherapy

Impact of Clinical-pathological Factors on Locoregional Recurrence in Mastectomy Patients with T1-2N1 Breast Cancer: Can We Omit Adjuvant Radiotherapy?

Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy

Outcomes in Patients with pT3N0M0 Breast Cancer with and without Postmastectomy Radiotherapy

Failure patterns of locoregional recurrence in women with T1-2N1 breast cancer after modified radical mastectomy

The Role of Postmastectomy Radiation Therapy in Locally Advanced Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Mastectomy

Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node-negative breast cancer patients treated with mastectomy: Implications for postoperative radiotherapy.

Postmastectomy Radiotherapy Improves Disease-Free Survival of High Risk of Locoregional Recurrence Breast Cancer Patients with T1-2 and 1 to 3 Positive Nodes

Radiotherapy Can Improve The Disease-Free Survival Rate In Triple-Negative Breast Cancer Patients With T1-T2 Disease And One To Three Positive Lymph Nodes After Mastectomy

Value of Postmasteetomy Radiotherapy in T_2 Breast Cancer Patients with 1-3 Positive Axillary Lymph Nodes

A Recurrence Risk Score Model Evaluating Effects of Postmastectomy Radiotherapy in Breast Cancer Patients with Pathologically Negative Lymph Nodes after Neoadjuvant Chemotherapy: A Multicenter, Retrospective Study

Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report

Radiotherapy following modified radical mastectomy significantly improves locoregional control in patients with Rec-/HER-2+ locally advanced breast cancer

Postmastectomy Radiation Therapy Reduces Locoregional Recurrence and Disease Recurrence in Triple-Negative Breast Cancer Patients with Stage Ii-Iii Treated with Neoadjuvant Chemotherapy and Mastectomy

Analysis In Early Stage Triple-Negative Breast Cancer Treated With Mastectomy Without Adjuvant Radiotherapy: Patterns Of Failure And Prognostic Factors